NTT-DOCOMO
16.1.2024 10:11:27 CET | Business Wire | Press release
NTT DOCOMO, INC. announced today that it will exhibit at MWC Barcelona 2024, the world's largest mobile exhibition, in Barcelona, Spain from February 26 to 29. DOCOMO's booth will showcase exhibits of its technological advancement since last year and presentations focused on the core themes of 6G, open radio access networks (Open RAN) and extended reality (XR), aiming to advance international standardization and foster global business opportunities with the implementation of next-generation communication technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116090399/en/
NTT DOCOMO Booth at MWC Barcelona 2024 (Graphic: Business Wire)
For 6G, there will be interactive demonstrations of FEEL TECH,® an innovative technology that revolutionizes the sharing of sensory information between people DOCOMO's Human Augmentation Platform connected to a 6G network. This pioneering technology aims to facilitate clear transmission of sensory information that is often difficult to communicate verbally, paving the way for a new communication culture and providing added value for an enhanced quality of life.
The booth will also provide a glimpse of the coming world of 6G and advanced wireless technologies that DOCOMO is now developing, such as a non-terrestrial network (NTN) incorporating high-altitude platform stations (HAPS),1 which are expected to facilitate the broad extension of communication services beyond the reach of conventional terrestrial network areas, from remote seas to low-orbit space.
For Open RAN, in addition to presenting the OREX®2-branded services (OREX Packages), DOCOMO will introduce the latest initiatives with diverse global vendors and operators since the launch of the OREX to make Open RAN a reality.
For XR, DOCOMO will showcase the first concept model3 of XR glasses from NTT QONOQ Devices, INC.,4 which is scheduled for release around mid-2024, along with images of utilization.
At MWC Barcelona 2024, DOCOMO looks forward to showcasing its cutting-edge technologies and businesses the company is developing under the brand slogan "changing worlds with you."
For more about DOCOMO's exhibits and the overall exhibition, please refer to the appendix.
1 Unmanned vehicles flying in the stratosphere for days or months at a time, using relays to provide mobile connectivity (ranging up to 200 kilometers) in mountainous and remote areas, including at sea and in the air, on a highly cost-efficient basis.
2 OREX Announces OREX® Open RAN Service Lineup https://www.docomo.ne.jp/english/info/media_center/pr/2023/0927_00.html
3 Specifications of final commercial products may differ from the reference exhibits.
4 NTT QONOQ, INC. and SHARP CORPORATION form a joint venture company, NTT QONOQ Devices, INC.
https://www.devices.nttqonoq.com/pdf/20230327.pdf
Human Augmentation Platform, FEEL TECH and OREX are registered trademarks of NTT DOCOMO, INC. in Japan.
About NTT DOCOMO
NTT DOCOMO, Japan's leading mobile operator with over 88 million subscriptions, is one of the world's foremost contributors to 3G, 4G and 5G mobile network technologies. Beyond core communications services, DOCOMO is challenging new frontiers in collaboration with a growing number of entities ("+d" partners), creating exciting and convenient value-added services that change the way people live and work. Under a medium-term plan toward 2020 and beyond, DOCOMO is pioneering a leading-edge 5G network to facilitate innovative services that will amaze and inspire customers beyond their expectations.
https://www.docomo.ne.jp/english/
Appendix
Overview of NTT DOCOMO Booth at MWC Barcelona 2024
1. Exhibitions |
||
Theme |
Exhibit & Demo |
Details |
6G |
Wireless technologies and NTN |
Non-terrestrial network initiatives for 6G and extended coverage, including technical explanations, dioramas and simulators. |
Human Augmentation Platform |
Platform and FEEL TECH technology for sharing sensory information between people. |
|
Open RAN |
Virtual tour of Shared Open Lab |
360-degree, 3D virtual tour of the OREX verification environment. |
Automated network design and maintenance |
Demonstrations of actual systems for automated network design and maintenance. |
|
XR |
Conceptual model of XR glasses |
Mock-up model and video illustrating how these proposed glasses will be used. |
2. NTT DOCOMO Booth Location
Hall 4 Stand 4E50
3. Presentation
Tentative title: Open RAN: Toward Commercialization and Operations
When: Monday, February 26 from 13:15 to 13:45 (local time)
Where: Broadcast Stage, Hall 4
Speaker: Mr. Sadayuki Abeta, OREX evangelist, NTT DOCOMO
Note: Content and schedule are subject to change. Please see MWC Barcelona 2024 for the latest information.
Reference
MWC Barcelona 2024
https://www.mwcbarcelona.com/
1. Dates & Times
February 26 to 29
08:30 to 19:00, but 08:30 to 16:00 on last day (all times local)
2. Venue
Fira Gran Via
Av. Joan Carles I, 64
08908 L'Hospitalet de Llobregat
Barcelona, Spain
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116090399/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom